{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T05:53:33Z","timestamp":1781243613766,"version":"3.54.1"},"reference-count":18,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T00:00:00Z","timestamp":1742688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Huntington's Disease"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Deutetrabenazine, a vesicular monoamine transporter 2 inhibitor, is one of few treatment options available for Huntington's disease (HD) chorea. There is limited data describing clinical experience with deutetrabenazine doses &gt;48\u2005mg daily.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Describe treatment outcomes for deutetrabenazine &gt;48\u2005mg daily.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A dual site retrospective cohort study of patients on deutetrabenazine titrated to doses &gt;48\u2005mg\/day for HD chorea from April 2017 through December 2021 was conducted. Patients using concomitant strong CYP2D6 inhibitors at time of deutetrabenazine initiation, those who became deceased or lost to follow-up within six months of dose increase above 48\u2005mg\/day, or previously enrolled in a study on &gt;48\u2005mg daily and moving to commercial product were excluded. Outcomes were reported descriptively including therapeutic response, adverse effects (AEs), adherence (measured by proportion of days covered [PDC]), and discontinuation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty patients were included: 47% female, 93% White, median age 56 years. Most patients required dose escalations for inadequate response. The rate of AEs reported before and after transitioning to doses &gt;48\u2005mg\/day was the same. Psychiatric changes were less commonly reported at doses &gt;48\u2005mg\/day, but extrapyramidal symptoms were more common. The median total maximum chorea score in the Unified HD Rating Scale was 13 (IQR 9\u201319) and 13 (IQR 7\u201318) at baseline and follow-up, respectively. Median PDC was 0.99 (IQR 0.94\u20131.00); two patients discontinued therapy due to AEs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Deutetrabenazine &gt;48\u2005mg daily appears safe and well tolerated in patients with uncontrolled HD chorea, though no significant change in total maximal chorea score was found.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/18796397251323293","type":"journal-article","created":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T02:24:31Z","timestamp":1742783071000},"page":"140-148","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Deutetrabenazine treatment outcomes with doses above U.S. Food and Drug Administration maximum approved doses in Huntington's disease chorea: A dual-site analysis"],"prefix":"10.1177","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-1506-2976","authenticated-orcid":false,"given":"Kayla","family":"Dodson","sequence":"first","affiliation":[{"name":"University of Tennessee Health Science Center College of Pharmacy, Nashville, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8565-0114","authenticated-orcid":false,"given":"Sabrina","family":"Livezey","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Vanderbilt Specialty Pharmacy, Nashville, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany","family":"Denson","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Alabama Birmingham, Birmingham, AL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leena","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8171-5766","authenticated-orcid":false,"given":"Josh","family":"DeClercq","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8376-0691","authenticated-orcid":false,"given":"Autumn D.","family":"Zuckerman","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Vanderbilt Specialty Pharmacy, Nashville, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2247-7307","authenticated-orcid":false,"given":"Kayla","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Vanderbilt Specialty Pharmacy, Nashville, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,3,23]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60111-1"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.29228"},{"key":"e_1_3_4_4_2","volume-title":"Austedo (deutetrabenazine) [package insert]","year":"2017","unstructured":"Austedo (deutetrabenazine) [package insert]. New Wales, PA: Teva Pharmaceuticals, 2017."},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.00710"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1186\/s42466-023-00285-1"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-022-00956-8"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.94.15_supplement.4310"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25422"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2008.08.010"},{"key":"e_1_3_4_12_2","article-title":"Risk of VMAT2 inhibitors on suicidality and parkinsonism: Report utilizing the United States Food and Drug Administration adverse event reporting system","author":"Wong S","unstructured":"Wong S, Le GH, Kwan ATH, et al. Risk of VMAT2 inhibitors on suicidality and parkinsonism: Report utilizing the United States Food and Drug Administration adverse event reporting system. Int Clin Psychopharmacol. Epub ahead of print 11 May 2024. DOI: https:\/\/doi.org\/10.1097\/YIC.0000000000000553.","journal-title":"Int Clin Psychopharmacol"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.8655"},{"key":"e_1_3_4_14_2","unstructured":"Pharmacy Quality Alliance. PQA Performance Measures Alexandria VA2017 [Available from: https:\/\/pqaalliance.org\/measures\/default.asp."},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-021-00309-5"},{"key":"e_1_3_4_16_2","first-page":"207","article-title":"Predictors of persistence and adherence to deutetrabenazine among patients with Huntington disease or tardive dyskinesia","volume":"13","author":"Claassen DO","year":"2023","unstructured":"Claassen DO, Ayyagari R, Garc\u00eda-Horton V, et al. Predictors of persistence and adherence to deutetrabenazine among patients with Huntington disease or tardive dyskinesia. Ment Health Clin 2023; 13: 207\u2013216.","journal-title":"Ment Health Clin"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmacy7040163"},{"key":"e_1_3_4_18_2","first-page":"95","article-title":"The effect of an integrated health system specialty pharmacy on HIV antiretroviral therapy adherence, viral suppression, and CD4 count in an outpatient infectious disease clinic","volume":"26","author":"Barnes E","year":"2020","unstructured":"Barnes E, Zhao J, Giumenta A, et al. The effect of an integrated health system specialty pharmacy on HIV antiretroviral therapy adherence, viral suppression, and CD4 count in an outpatient infectious disease clinic. J Manag Care Spec Pharm 2020; 26: 95\u2013102.","journal-title":"J Manag Care Spec Pharm"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2018.24.4.317"}],"container-title":["Journal of Huntington's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/18796397251323293","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/18796397251323293","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/18796397251323293","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:56:32Z","timestamp":1777452992000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/18796397251323293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,23]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1177\/18796397251323293"],"URL":"https:\/\/doi.org\/10.1177\/18796397251323293","relation":{},"ISSN":["1879-6397","1879-6400"],"issn-type":[{"value":"1879-6397","type":"print"},{"value":"1879-6400","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,23]]}}}